UBS analyst Eliana Merle maintains $Apellis Pharmaceuticals (APLS.US)$ with a buy rating, and adjusts the target price from $83 to $45.
According to TipRanks data, the analyst has a success rate of 39.4% and a total average return of -5.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
Following the Q3 report, there's an identification of a distinct opportunity to develop a new thesis for 'post-GA' that is firmly rooted in the strong belief in the potential of C3G and IC-MPGN. The data for these are considered exceptionally robust and are viewed as superior to that of the oral competitor, especially in a wider context.
Following Apellis's report of Q3 Syfovre revenues that did not meet expectations, there remains anticipation for further insights into the geographic atrophy market's scope. Despite this, the valuation at present appears to underestimate the prospective market size, with the prospective introduction in C3G/IC-MPGN possibly mitigating the more gradual growth observed in the GA segment.
Apellis disclosed third-quarter results, which reflected a decrease in Syfovre revenue due to modest growth in vial numbers alongside a reduction in net pricing and heightened competition.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
